卡氏肺孢子虫
肺炎
免疫学
肺孢子虫肺炎
医学
耶氏肺孢子虫
戊脒
病毒学
人类免疫缺陷病毒(HIV)
生物
重症监护医学
内科学
出处
期刊:Archives of internal medicine
[American Medical Association]
日期:1995-06-12
卷期号:155 (11): 1125-1128
被引量:138
标识
DOI:10.1001/archinte.155.11.1125
摘要
MORE THAN 80 years after its identification in the lungs of rats by Chagas and Carini, and 50 years after its establishment as the cause of epidemic plasma cell pneumonitis in malnourished or premature infants,1Pneumocystis cariniicontinues to puzzle and surprise. Fundamental debates continue about its taxonomy (fungus or protozoan) and transmissibility. In addition, there is no reliable way to cultivate the organism in vitro. Despite these gaps in basic information, the optimal treatment and prophylaxis ofP cariniipneumonia (PCP) are well established. Landmark studies by Hughes et al2-4demonstrated the central role of sulfamethoxazole-trimethoprim in the treatment and prevention of this disease. In the 1980s, the high rates of PCP occurring among persons infected with human immunodeficiency virus (HIV) largely overshadowed its role as a pathogen among the HIV negative. For example, in 1992, PCP accounted for 42% of all acquired immunodeficiency syndrome—indicator diseases reported
科研通智能强力驱动
Strongly Powered by AbleSci AI